Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Light Street Stung by July Tech Rout, Still Tops Broader Market Stephen Taub For Members Only Biotech IPO Fever Shows No Signs of Breaking Stephen Taub What Past Sector Concentrations Tell Us About Today's Tech-Heavy S&P 500 Sponsored by CME Group